Evolocumab公司
医学
安慰剂
内科学
冲程(发动机)
心脏病学
心肌梗塞
糖尿病
PCSK9
2型糖尿病
他汀类
随机化
不利影响
随机对照试验
耐受性
阿利罗库单抗
相对风险
兴奋剂
血管疾病
意向治疗分析
相伴的
低风险
作者
Lawrence A. Leiter,Robert Patrick Giugliano,Nicholas Marston,Gaetano Ferrari,José Carlos Nicolau,Ajay K. Bhatia,Marcoli Cyrille,J Park,Julia Kuder,Sabina A. Murphy,Lyrica Liu,Emileigh Walsh,Huei Wang,Andrej Džupina,Jorge Ferreira,Ioanna Gouni‐Berthold,Henrik Kjærulf Jensen,Johanna Kuusisto,Daniel Pella,Naveed A. Sattar
出处
期刊:Diabetes Care
[American Diabetes Association]
日期:2026-06-07
卷期号:49 (8): 1366-1373
被引量:4
摘要
OBJECTIVE: This prespecified analysis of Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV) evaluated the efficacy of the PCSK9 inhibitor evolocumab for preventing first cardiovascular events in patients with high-risk diabetes. RESEARCH DESIGN AND METHODS: VESALIUS-CV randomized patients with high-risk diabetes (microvascular disease, insulin use, or duration ≥10 years) or qualifying atherosclerosis, but no prior myocardial infarction (MI) or stroke, and LDL cholesterol (LDL-C) ≥90 mg/dL to evolocumab 140 mg or matching placebo every 2 weeks. The dual primary end points were a composite of coronary heart disease death, MI or ischemic stroke (three-point major adverse cardiovascular event [3P-MACE]) and 3P-MACE plus ischemia-driven arterial revascularization (four-point [4P]-MACE). RESULTS: Of the 6,002 patients with high-risk diabetes, 67% were on a high-intensity statin and 24% were on a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 receptor agonist (GLP-1RA) at baseline. The median LDL-C at 48 weeks was 47 mg/dL and 109 mg/dL in the evolocumab and placebo arms, respectively (P < 0.0001). After a median follow-up of 4.6 years, evolocumab decreased the relative rates of 3P-MACE and 4P-MACE by 29% (hazard ratio [HR] 0.71; 95% CI 0.59, 0.86; P = 0.0004) and 21% (HR 0.79; 95% CI 0.69, 0.91; P = 0.0013), respectively. These findings were consistent regardless of the presence or absence of qualifying atherosclerosis, baseline LDL-C, statin intensity, and SGLT2i or GLP-1RA use (Pint > 0.05 for each). The porportion of patients with all-cause death was 8.8% vs. 11.0% in the evolocumab versus placebo arms (HR 0.79; 95% CI 0.67, 0.93). CONCLUSIONS: Evolocumab reduced the rate of cardiovascular events in patients with high-risk diabetes, regardless of the presence or absence of qualifying atherosclerosis and background use of other cardioprotective agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI